Perspective Therapeutics: Clinical Trials

6 trials sponsored by Perspective Therapeutics, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 2 active not recruiting, 1 completed. 4 Phase 1, 3 Phase 2, 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 14Recruiting 3, Completed 1
Phase 23Recruiting 3
Early Phase 12Active not recruiting 2

Follow Perspective Therapeutics: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lead-212 PSV359 Therapy for Patients With Solid Tumors
[203Pb]Pb-PSV359, [212Pb]Pb-PSV359 - Pancreatic Ductal Adenocarcinoma, Gastric Cancer
Phase 1 / Phase 2RecruitingPerspective Therapeutics1122025-04-282026-10-28
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
[212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT - Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung
Early Phase 1Active not recruitingDavid Bushnell242023-11-102025-11-04
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
[203Pb]VMT-α-NET, [212Pb]VMT-α-NET - Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Phase 1 / Phase 2RecruitingPerspective Therapeutics3002023-09-272026-10-13
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
[203Pb]VMT01, [212Pb]VMT01, Nivolumab - Recurrent Melanoma (Skin), Metastatic Melanoma
Phase 1 / Phase 2RecruitingPerspective Therapeutics3002023-06-012026-10-13
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
[203Pb]VMT-α-NET, SPECT/CT - Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1
Early Phase 1Active not recruitingYusuf Menda202022-08-222025-07-14
Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy
[203Pb]VMT01, [68Ga]VMT02 - Melanoma (Skin), Melanoma Stage IV
Phase 1CompletedPerspective Therapeutics72021-03-052023-11-07

Conditions studied

Melanoma (2)  ·  Neuroendocrine Tumors (2)  ·  Adenoma, Islet Cell (1)  ·  Colorectal Neoplasms (1)  ·  Disease (1)  ·  Esophageal Neoplasms (1)  ·  Gastro-enteropancreatic neuroendocrine tumor (1)  ·  Head and Neck Neoplasms (1)  ·  Meningioma (1)  ·  Mesothelioma (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Ovarian Neoplasms (1)  ·  Paraganglioma (1)  ·  Pheochromocytoma (1)

Interventions

Nivolumab (1)  ·  Single Photon Emission Computed Tomography Computed Tomography (1)

Countries

United States (6)

Top investigators

David Bushnell, MD (1)  ·  Frances L Johnson, MD (1)  ·  Geoffrey B Johnson, MD, PhD (1)  ·  Yusuf Menda, M.D. (1)

Results publications

PMID 41644295, PMID 42306799

NIH funding

R01CA243014 (2)